

## Anti-Seizure Agents (Epidiolex & Fintepla) Prior Authorization of Benefits Form

## CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 844-474-3341.

1. Patient information	2. Physician information		
Patient name:	Prescribing physician:	Prescribing physician:	
Patient ID #:	Physician address:	Physician address:	
Patient DOB:	Physician phone #:	Physician phone #:	
Date of Rx:	Physician fax #:		
Patient phone #:	Physician specialty:	Physician specialty:	
Patient email address:	Physician DEA:	Physician DEA:	
	Physician NPI #:		
3. Medication 4. Strength	5. Directions	6. Quantity per 30 days	
		Specify:	
7. Diagnosis:	L	. <b>L</b>	
<b>8. Approval criteria:</b> (Check all boxes that apply. patient and may affect the outcome of this reques		onsidered not applicable to your	
☐ Yes ☐ No Does the patient have a diagnosis of For the <i>Texas Medicaid Preferred Drug List</i> , please https://www.txvendordrug.com/formulary/form	of Dravet syndrome in the last 730 d of tuberous sclerosis complex in the e refer to the Texas Medicaid Vendo	ays? last 730 days?	
9. Physician signature			
Prescriber or authorized signature  Date  Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only			
treating physician can determine what medications are appropregarding benefits, conditions, limitations and exclusions. The complete and the requested services are medically indicated an eligibility. Authorization does not guarantee payment.	submitting provider certifies that the inform nd necessary to the health of the patient. No	nation provided is true, accurate and	

Amerigroup members in the Medicaid Rural Service Area and the STAR Kids program are served by Amerigroup Insurance Company; all other Amerigroup members in Texas are served by Amerigroup Texas, Inc.

error, please notify the sender immediately and arrange for the return or destruction of these documents

TXAGP-CD-008754-22 September 2022

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from dis closing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in